Journal of Clinical Oncology
Articles in this Issue
Population-based survival and demographic disparities in acute megakaryoblastic leukemia with t(1;22)(p13;q13); RBM15–MKL1: A SEER analysis (2000–2021).
e18550 Background: Acute megakaryoblastic leukemia (AMKL) with t(1;22)(p13;q13); RBM15–MKL1 is a rare, genetically defined...
Pancreatic cancer incidence and survival in lean and obese adults with type 2 diabetes: A propensity matched analysis.
10576 Background: Type 2 diabetes mellitus (T2DM) and excess adiposity are independent risk factors for pancreatic cancer....
Artificial intelligence–based predictive models for recurrence and recurrence-free survival in gastrointestinal stromal tumors: A contemporary systematic review.
11536 Background: Recurrence after complete resection of GISTs is still a major contributing factor to long-term survival....
Mortality trends involving colon cancer and atrial fibrillation in the United States,1999-2023: A CDC WONDER analysis.
e24021 Background: Colon cancer is a leading cause of cancer-related mortality in the United States, while atrial fibrilla...
Real-time liquid biopsy guided assessment of radiation response: Longitudinal circulating free DNA kinetics during precision radiotherapy across solid tumors from India.
e15056 Background: Precision radiotherapy has improved dose delivery, but biological response assessment is delayed, espec...
Impact of the 2022 NCCN Guideline Update on germline testing in early-onset colorectal cancer: Insights from a large tertiary referral center.
e15741 Background: In 2022, the NCCN expanded guidelines to recommend universal germline genetic testing for patients diag...
Ivonescimab (ivo) with oxaliplatin + fluorouracil (5-FU) + leucovorin calcium (mFOLFOX6) for patients (pts) with unresectable metastatic colorectal cancer (mCRC): A phase 2 study.
3576 Background: Ivonescimab is an investigational tetrameric bispecific antibody targeting both programmed death protein...
Targeted outreach and fecal immunochemical testing (FIT) completion among vulnerable Rhode Island populations.
e22516 Background: Colorectal cancer (CRC) is the second leading cause of cancer death in the United States, with dispropo...
Comparative analysis of neoadjuvant chemoimmunotherapy (chemoIO) versus PD-(L)1 monotherapy (mono) across PD-L1 expression strata in resectable non–small cell lung cancer (NSCLC): A systematic review and meta-analysis of prospective trials.
e20069 Background: Neoadjuvant chemoIO is a standard treatment for resectable NSCLC, and PD-L1 expression correlates with...
A baicalein and oxaliplatin co-loaded nano-delivery system for dual gasdermin-mediated pyroptosis in pancreatic ductal adenocarcinoma.
e16456 Background: Pancreatic ductal adenocarcinoma (PDAC) features a highly immunosuppressive tumor microenvironment (TME...
Demographic characteristics and inpatient outcomes of early-onset pancreatic cancer in the United States.
e16356 Background: Pancreatic cancer (PC) is a leading cause of cancer-related deaths, with a 5-year relative survival rat...
Trends in ivermectin medication records with cancer as the primary diagnosis following public attention: A national EHR analysis.
11121 Background: Ivermectin, an antiparasitic agent not indicated for cancer treatment, has received public attention sin...
Survival outcomes following salvage surgery for recurrent and residual head and neck squamous cell carcinoma after chemoradiotherapy.
e18066 Background: Recurrent or residual head and neck squamous cell carcinoma (HNSCC) after chemoradiotherapy (CRT) is as...
Tyrosine kinase inhibitors in Philadelphia chromosome–positive acute lymphoblastic leukemia (ALL): A systematic review and meta-analysis.
e18522 Background: Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) is a rare, life threatening for...
Second-line cetuximab plus immune checkpoint inhibitor (ICI) versus cetuximab plus carboplatin and paclitaxel following ICI-containing regimen in recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC).
6046 Background: ICI-containing regimens are the standard first-line therapies for R/M HNSCC. However, the optimal therape...
Machine learning to identify racial and socioeconomic disparities in the onset and tumor distribution of second primary malignancies in multiple myeloma.
7551 Background: As survival in Multiple Myeloma (MM) improved with novel therapies, the burden of second primary malignan...
Histopathological distinction between ICI-induced psoriasis vulgaris and psoriasiform dermatitis in patients with immune-related cutaneous adverse events (irDAEs): A multicenter prospective observational study.
e24191 Background: Immune checkpoint inhibitors (ICI) significantly improve survival in cancer patients but are frequently...
ChatGPT-based conversational AI tool for training oncologists in patient communication: A real-world implementation study.
e13675 Background: Oncologists frequently experience difficulties communicating with patients, particularly when deliverin...
Real-world overall survival outcomes of belzutifan treatment in advanced renal cell carcinoma.
4561 Background: Belzutifan, a hypoxia-inducible factor–2α inhibitor, is an emerging therapy for advanced renal cell carci...
Oral selective estrogen receptor degraders in HR+/HER2- advanced breast cancer and impact of ESR1 mutation status: A systematic review and meta-analysis.
1081 Background: Oral selective estrogen receptor degraders (SERDs) are a promising therapeutic class for hormone receptor...
Impact of para-aortic lymphadenectomy on prognosis and quality of life in preoperative IB2-IIA2 cervical cancer: A multi-center cohort study.
5528 Background: The indication of para-aortic lymphadenectomy (PALD) in preoperative IB2-IIA2 (FIGO 2018) cervical cancer...
Impact of surgical timing on outcomes in patients with borderline-resectable and locally advanced pancreatic cancer undergoing neoadjuvant therapy.
e16460 Background: Neoadjuvant therapy (NAT) followed by resection is standard for borderline-resectable (BR) pancreatic d...
Durvalumab plus chemotherapy prior to chemoradiotherapy and followed by durvalumab as consolidation for patients with limited-stage small cell lung cancer (CONCUR study).
TPS8139 Background: The ADRIATIC study demonstrated that durvalumab consolidation therapy following concurrent chemoradiot...
Automated detection of tertiary lymphoid structures (TLS) on whole-slide pathology images using an improved YOLO-v12 model and validation of a TLS structural prognostic index (TLS-SPI) across multi-cancer TCGA cohorts.
e13670 Background: Tertiary lymphoid structures (TLS) are important biomarkers reflecting the tumor immune microenvironmen...
POLARIS: Polymetastatic lesion ablative radiotherapy with immunotherapy study.
TPS2683 Background: Patients with polymetastatic disease, most commonly defined as >5 metastatic lesions, often have li...